The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2022 | Improving outcomes in KRAS-mutant pancreatic cancer

Name: Improving outcomes in KRAS-mutant pancreatic cancer
Uploaded: 2022-06-06T00:00:00Z
Duration: 41 s
Description: John H. Strickler, MD, Duke Cancer Institute, Durham, NC, discusses the use of sotorasib and KRAS inhibitors in pancreatic cancer, as well as potential combinations to improve outcomes in KRAS-mutant patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

John Strickler • 6 Jun 2022

ASCO 2022

Gastrointestinal Cancer Pancreatic Cancer Sotorasib

John H. Strickler, MD, Duke Cancer Institute, Durham, NC, discusses the use of sotorasib and KRAS inhibitors in pancreatic cancer, as well as potential combinations to improve outcomes in KRAS-mutant patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.